Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Phase 1b/2 Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment

NCT01136733 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT01136733
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01136733 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Phase 1b/2 Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment
Lead sponsor
Eisai Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
August 5, 2010
Completion date
February 8, 2018
Enrollment
173 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic renal cell carcinoma